Moderna-Merck mRNA Cancer Vaccine Beats Keytruda Alone in Phase 3 Melanoma Trial
Merck and Moderna announced on August 19, 2026, that their personalized mRNA-based cancer vaccine met the main goals of a late-stage trial in melanoma, a result oncologists are calling a milestone for